Therapeutics News and Research

RSS

Researchers develop a versatile tool for controlling gene activity

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of any gene in a cell. Such "gene-switch" tools allow scientists to "turn on" or "turn off" a target gene to study how it works, model diseases and design new therapies.

3 Nov 2025

Molecular bumpers and glues rewire GPCR signaling for next-generation medicines

New research led by the University of Minnesota Medical School demonstrates that molecules acting as "molecular bumpers" and "molecular glues" can rewire G protein-coupled receptor (GPCR) signaling, turning the cell's busiest receptors into precision tools - opening the door to a new generation of safer, smarter medicines.

31 Oct 2025

Sirolimus-eluting balloon emerges as a safe and effective option for coronary in-stent restenosis

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI).

31 Oct 2025

How nerve cells in the gut adapt to microbial and immune challenges

Ramnik Xavier, MD, PhD, of the Department of Molecular Biology at Massachusetts General Hospital, is the senior author of a paper published in Science, "Regional encoding of enteric nervous system responses to microbiota and type 2 inflammation."

31 Oct 2025

Breakthrough could offer a new therapeutic option for stopping diabetes-induced complications

Researchers from the University at Albany and NYU Grossman School of Medicine have found a way to block a key cellular pathway known to drive chronic inflammation and impaired wound healing in people with diabetes.

30 Oct 2025

Scripps Research professor wins $3.2 million grant to unravel the mysteries of type 1 diabetes

Luc Teyton, professor in the Department of Immunology and Microbiology at Scripps Research, has received a five-year, $3.2 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to help answer how type 1 diabetes manifests and develop potential therapeutics to reverse or prevent the disease.

29 Oct 2025

Systematic analysis reveals psilocybin's impact on obsessive-compulsive behaviors

A systematic review published today in Psychedelics by Mr. James Gattuso and colleagues at the Florey Institute of Neuroscience and Mental Health synthesizes clinical and preclinical evidence on psilocybin's effects on obsessive-compulsive behaviors, revealing consistent therapeutic potential across human patients and validated animal models.

29 Oct 2025

Specialized type of cardiac fibroblasts can actively worsen heart failure

Heart failure (HF) is one of the leading causes of death and disability worldwide, affecting millions of people and placing an enormous burden on healthcare systems.

29 Oct 2025

Experimental compound reduces cell death, inflammation, and organ damage in diabetes

An experimental compound reduced the cell death, inflammation, and organ damage seen with diabetes.

29 Oct 2025

Treating patients at home with IV antibiotics could halve costs to the NHS

Treating patients at home with IV antibiotics, rather than in a clinical setting, could halve costs to the NHS and relieve pressure on hospital beds - according to a University of East Anglia study.

29 Oct 2025

Study highlights non-inferiority of super-high-pressure non-compliant balloons in coronary interventions

New study findings show that utilizing super-high-pressure non-compliant balloons (NCB) is non-inferior to intravascular lithotripsy (IVL) balloon catheters for lesion preparation and stent expansion in severely calcified lesions during percutaneous coronary intervention (PCI).

28 Oct 2025

Landmark trial shows drug-eluting balloon as effective option for in-stent restenosis

Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to control group consisting of drug-eluting stent (DES) and balloon angioplasty (BA) for the treatment of bare-metal and DES in-stent restenosis (ISR) deemed DEB to be noninferior to conventional therapies.

28 Oct 2025

Cutting balloon angioplasty proves noninferior to intravascular lithotripsy in treating calcified coronary lesions

Results from the first randomized controlled trial to directly compare the safety and efficacy of cutting balloon (CB) angioplasty to intravascular lithotripsy (IVL) prior to drug-eluting stent (DES) implantation for the treatment of calcified coronary artery disease found CB to be noninferior to IVL.

28 Oct 2025

Mount Sinai receives $4.5 million grant to investigate neural mechanisms underlying bipolar disorder

The Icahn School of Medicine at Mount Sinai is pleased to announce it has received a three-year, $4.5 million grant from BD2: Breakthrough Discoveries for thriving with Bipolar Disorder to investigate the neural mechanisms underlying bipolar disorder and pioneer novel neuromodulation-based treatment strategies.

28 Oct 2025

BD² expands global effort to examine the key mechanisms of bipolar disorder

Today, BD², or Breakthrough Discoveries for thriving with Bipolar Disorder, announced its third round of Discovery Research grants, totaling nearly $18 million – expanding a comprehensive global effort to examine the key mechanisms of bipolar disorder.

28 Oct 2025

Electronic health record data reveals trends in cardiovascular diseases before and after COVID-19

The electronic health record data analyzed in this study is anonymized and never leaves a secure data environment, which is only accessible by approved researchers working on approved projects.

28 Oct 2025

Clinically significant valvular heart disease vastly underdiagnosed in U.S. elders

Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65-85 living with moderate or greater valvular heart disease (VHD) in the United States, and at least 10.6 million with clinically significant VHD, most of whom are unaware of their condition.

28 Oct 2025

Fogarty Innovation and CRF unite to accelerate breakthroughs in cardiovascular medicine

After several years of close collaboration and a relationship rooted in mutual respect and shared vision, Fogarty Innovation is coming together with the Cardiovascular Research Foundation® (CRF®) to create a unified platform for advancing transformative healthcare technologies.

27 Oct 2025

Sirolimus-eluting balloon strategy matches drug-eluting stents in large international PCI trial

New study results from a large international all-comer population of percutaneous coronary intervention (PCI) candidates found that utilizing a strategy of sirolimus-eluting balloons with bailout stenting only if necessary was noninferior to routine drug-eluting stent (DES) implantation as part of the treatment for de novo coronary artery disease.

27 Oct 2025

Daily 40Hz audiovisual stimulation may slow cognitive decline in late-onset Alzheimer's patients

A new research paper documents the outcomes of five volunteers who continued to receive 40Hz light and sound stimulation for around two years after participating in an MIT early-stage clinical study of the potential Alzheimer's disease therapy.

27 Oct 2025

Therapeutics News and Research

Researchers develop a versatile tool for controlling gene activity

Molecular bumpers and glues rewire GPCR signaling for next-generation medicines

Sirolimus-eluting balloon emerges as a safe and effective option for coronary in-stent restenosis

How nerve cells in the gut adapt to microbial and immune challenges

Breakthrough could offer a new therapeutic option for stopping diabetes-induced complications

Scripps Research professor wins $3.2 million grant to unravel the mysteries of type 1 diabetes

Systematic analysis reveals psilocybin's impact on obsessive-compulsive behaviors

Specialized type of cardiac fibroblasts can actively worsen heart failure

Experimental compound reduces cell death, inflammation, and organ damage in diabetes

Treating patients at home with IV antibiotics could halve costs to the NHS

Study highlights non-inferiority of super-high-pressure non-compliant balloons in coronary interventions

Landmark trial shows drug-eluting balloon as effective option for in-stent restenosis

Cutting balloon angioplasty proves noninferior to intravascular lithotripsy in treating calcified coronary lesions

Mount Sinai receives $4.5 million grant to investigate neural mechanisms underlying bipolar disorder

BD² expands global effort to examine the key mechanisms of bipolar disorder

Electronic health record data reveals trends in cardiovascular diseases before and after COVID-19

Clinically significant valvular heart disease vastly underdiagnosed in U.S. elders

Fogarty Innovation and CRF unite to accelerate breakthroughs in cardiovascular medicine

Sirolimus-eluting balloon strategy matches drug-eluting stents in large international PCI trial

Daily 40Hz audiovisual stimulation may slow cognitive decline in late-onset Alzheimer's patients

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News